Recombinant
RabMAb

Anti-Pirh2 antibody [EPR18553] (ab189907)

Submit an Abreview Submit a Question

Overview

  • Product name
    Anti-Pirh2 antibody [EPR18553]
    See all Pirh2 primary antibodies
  • Description
    Rabbit monoclonal [EPR18553] to Pirh2
  • Host species
    Rabbit
  • Tested applications
    Suitable for: ICC/IF, IP, WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide within Human Pirh2 aa 150-250. The exact sequence is proprietary.
    Database link: Q96PM5

  • Positive control
    • WB: HEK-293, HCT 116, LNCaP, RAW 264.7 and NIH/3T3 whole cell lysates; Human fetal heart, fetal kidney and fetal spleen lysates; Mouse kidney and spleen lysates. ICC/IF: HeLa and HEK-293 cells. IP: HeLa whole cell lysate.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab189907 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/500.
IP 1/50.
WB 1/1000. Detects a band of approximately 30 kDa (predicted molecular weight: 30 kDa).

Target

  • Function
    Mediates E3-dependent ubiquitination and proteasomal degradation of target proteins, including p53/TP53, HDAC1 and CDKN1B. Preferentially acts on tetrameric p53/TP53. Contributes to the regulation of CDKN1B and p53/TP53 levels, and thereby contributes to the regulation of the cell cycle progression. Increases AR transcription factor activity.
  • Pathway
    Protein modification; protein ubiquitination.
  • Sequence similarities
    Contains 1 CHY-type zinc finger.
    Contains 1 CTCHY-type zinc finger.
    Contains 1 RING-type zinc finger.
  • Post-translational
    modifications
    Subject to ubiquitination and proteasomal degradation. Interaction with PLAGL2 or KAT5 enhances protein stability.
  • Cellular localization
    Nucleus. Nucleus speckle. Cytoplasm.
  • Information by UniProt
  • Database links
    • Alternative names
      • Androgen receptor N terminal interacting protein antibody
      • Androgen receptor N-terminal-interacting protein antibody
      • ARNIP antibody
      • CH-rich-interacting match with PLAG1 antibody
      • CHIMP antibody
      • E3 ubiquitin-protein ligase Pirh2 antibody
      • hARNIP antibody
      • hPirh2 antibody
      • p53 induced protein with a RING H2 domain antibody
      • p53-induced RING-H2 protein antibody
      • PIRH2E antibody
      • PIRH2F antibody
      • PRO1996 antibody
      • RCHY1 antibody
      • Ring finger and CHY zinc finger domain containing 1 E3 ubiquitin protein ligase antibody
      • RING finger and CHY zinc finger domain-containing protein 1 antibody
      • RING finger protein 199 antibody
      • RNF199 antibody
      • ZCHY antibody
      • ZFP 363 antibody
      • zinc finger CHY type antibody
      • Zinc finger protein 363 antibody
      • ZN363_HUMAN antibody
      • ZNF363 antibody
      see all

    Images

    • Western blot - Anti-Pirh2 antibody [EPR18553] (ab189907)
      Western blot - Anti-Pirh2 antibody [EPR18553] (ab189907)
      All lanes : Anti-Pirh2 antibody [EPR18553] (ab189907) at 1/1000 dilution

      Lane 1 : HEK-293 (Human epithelial cells from embryonic kidney) whole cell lysate
      Lane 2 : HCT 116 (Human colorectal carcinoma cell line) whole cell lysate
      Lane 3 : LNCaP (Human prostate cancer cell line) whole cell lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Predicted band size: 30 kDa
      Observed band size: 30 kDa


      Exposure time: 3 minutes


      Blocking/Dilution buffer: 5% NFDM/TBST.

    • Western blot - Anti-Pirh2 antibody [EPR18553] (ab189907)
      Western blot - Anti-Pirh2 antibody [EPR18553] (ab189907)
      All lanes : Anti-Pirh2 antibody [EPR18553] (ab189907) at 1/1000 dilution

      Lanes 1 & 3 : Human fetal heart lysate
      Lane 2 : Human fetal kidney lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/10000 dilution

      Predicted band size: 30 kDa
      Observed band size: 30 kDa


      Exposure time: 30 seconds


      Blocking/Dilution buffer: 5% NFDM/TBST.

    • Western blot - Anti-Pirh2 antibody [EPR18553] (ab189907)
      Western blot - Anti-Pirh2 antibody [EPR18553] (ab189907)
      All lanes : Anti-Pirh2 antibody [EPR18553] (ab189907) at 1/1000 dilution

      Lane 1 : Mouse kidney lysate
      Lane 2 : Mouse spleen lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Predicted band size: 30 kDa
      Observed band size: 30 kDa


      Exposure time: 3 minutes


      Blocking/Dilution buffer: 5% NFDM/TBST.

    • Western blot - Anti-Pirh2 antibody [EPR18553] (ab189907)
      Western blot - Anti-Pirh2 antibody [EPR18553] (ab189907)
      All lanes : Anti-Pirh2 antibody [EPR18553] (ab189907) at 1/1000 dilution

      Lane 1 : RAW 264.7 (Mouse macrophage cells transformed with Abelson murine leukemia virus) whole cell lysate
      Lane 2 : NIH/3T3 (Mouse embyro fibroblast cells) whole cell lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Predicted band size: 30 kDa
      Observed band size: 30 kDa


      Exposure time: 3 minutes


      Blocking/Dilution buffer: 5% NFDM/TBST.

    • Immunocytochemistry/ Immunofluorescence - Anti-Pirh2 antibody [EPR18553] (ab189907)
      Immunocytochemistry/ Immunofluorescence - Anti-Pirh2 antibody [EPR18553] (ab189907)

      Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (Human epithelial cells from cervix adenocarcinoma) cells labeling Pirh2 with ab189907 at 1/500 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).

      Confocal image showing nuclear and cytoplasmic staining on HeLa cell line.

      The nuclear counterstain is DAPI (blue).

      Tubulin is detected with ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution and ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/1000 dilution (red).

      The negative controls are as follows:-

      -ve control 1: ab189907 at 1/500 dilution followed by ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/1000 dilution.

      -ve control 2: ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution followed by ab150077 (Alexa Fluor®488 Goat Anti-Rabbit IgG H&L) at 1/1000 dilution.

    • Immunocytochemistry/ Immunofluorescence - Anti-Pirh2 antibody [EPR18553] (ab189907)
      Immunocytochemistry/ Immunofluorescence - Anti-Pirh2 antibody [EPR18553] (ab189907)

      Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HEK-293 (Human epithelial cells from embryonic kidney) cells labeling Pirh2 with ab189907 at 1/500 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).

      Confocal image showing nuclear and cytoplasmic staining on HEK-293 cell line.

      The nuclear counterstain is DAPI (blue).

      Tubulin is detected with ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution and ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/1000 dilution (red).

      The negative controls are as follows:-

      -ve control 1: ab189907 at 1/500 dilution followed by ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/1000 dilution.

      -ve control 2: ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution followed by ab150077 (Alexa Fluor®488 Goat Anti-Rabbit IgG H&L) at 1/1000 dilution.

    • Immunoprecipitation - Anti-Pirh2 antibody [EPR18553] (ab189907)
      Immunoprecipitation - Anti-Pirh2 antibody [EPR18553] (ab189907)

      Pirh2 was immunoprecipitated from 1mg of HeLa (Human epithelial cells from cervix adenocarcinoma) whole cell lysate with ab189907 at 1/50 dilution.

      Western blot was performed from the immunoprecipitate using ab189907 at 1/1000 dilution.

      VeriBlot for IP secondary antibody (HRP) (ab131366), was used as secondary antibody at 1/10000 dilution.

      Lane 1: HeLa whole cell lysate 10ug (Input).

      Lane 2: ab189907 IP in HeLa whole cell lysate.

      Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab189907 in HeLa whole cell lysate.

      Blocking and dilution buffer and concentration: 5% NFDM/TBST.

      Exposure time: 30 seconds.

    References

    ab189907 has not yet been referenced specifically in any publications.

    Publishing research using ab189907? Please let us know so that we can cite the reference in this datasheet.

    Customer reviews and Q&As

    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab189907.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up